Eroxon®
Erectile Dysfunction (ED)
Approved/CommercialMarketed OTC in over 15 countries including USA, UK, EU, Mexico, Middle East. Launched March 2023.
Key Facts
Indication
Erectile Dysfunction (ED)
Phase
Approved/Commercial
Status
Marketed OTC in over 15 countries including USA, UK, EU, Mexico, Middle East. Launched March 2023.
Company
About Futura Medical
Futura Medical has transitioned from a pre-revenue R&D group to a commercial-stage company with its lead product, Eroxon®, now available in over 15 countries worldwide. The company's strategy focuses on addressing the large, underserved OTC sexual health market through innovative, topically delivered gel formulations, with a pipeline that includes Eroxon® Intense and a women's health product, WSD4000. By partnering with leading consumer healthcare giants for marketing and distribution, Futura aims to leverage their resources and expertise to drive sales, build brand awareness, and achieve sustained profitability.
View full company profile